Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2341 to 2355 of 9088 results

  1. Botulinum neurotoxin type E for treating moderate to severe glabellar lines [TSID12155]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. TAK-880 for managing primary immunodeficiency diseases in people hypersensitive to IgA [TSID11883]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Insertion of Stoma Preservation Device

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  4. Subcutaneous efgartigmod for treating generalised myasthenia gravis [TSID11835]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Lutetium (177Lu) oxodotreotide for treating SSTR-positive advanced or inoperable gastroenteropancreatic neuroendocrine tumours in people 12 to 17 years [TSID12154]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Endoscopic ultrasound guided radiofrequency ablation (EUS-RFA) system for pancreatic cystic neoplasms and neuroendocrine tumours

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  7. Leniolisib for untreated activated phosphoinositide 3-kinase delta syndrome in children 4 to 11 years [TSID12190]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Dabrafenib for treating unresectable or metastatic BRAF V600 mutation positive melanoma in people 12 to 17 years [TSID12399]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Dabrafenib with trametinib for treating unresectable or metastatic BRAF V600 mutation positive melanoma in people 12 to 17 years [TSID12398]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Peginterferon alfa-2a for treating polycythaemia vera or essential thrombocythaemia [TSID12325]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Ponatinib for treating recurrent or refractory chronic myeloid leukaemia in people 1 to 17 years when another tyrosine kinase inhibitor is unsuitable [TSID12041]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Peroral endoscopic myotomy (POEM) for achalasia

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  14. Chemical Component Separation

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  15. Degradable surgical implant

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation